Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma

Pan, Jianji; Zhang, Shanwen; Chen, Chuan-beng; Xiao, Shan; Sun, Yan; Liu, Changqin; Su, Xing; Li, Dongming; Xu, Gang; Xu, Bin; Lu, Ye

doi:10.1200/jco.2008.18.9670

Cited by 107 publications

(81 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This high efficiency in inducing apoptosis results from the enhanced localization of the p53 codon 72 Arg/Arg genotype to mitochondria (Dumont et al, 2003). Previous clinical studies indicated that p53 codon 72 variants were associated with the clinical outcome of NPC (Alajez et al, 2009;Pan et al, 2009;Xie et al, 2013). Xie et al (2013) reported that the p53 codon 72 Pro/Pro genotype may be an effective independent prognostic marker for better outcome in patients with locoregional NPC, and positive protein expression and local regional lymph node metastasis can predict the progression of NPC.…”

Section: Discussionmentioning

confidence: 99%

“…Xie et al (2013) reported that the p53 codon 72 Pro/Pro genotype may be an effective independent prognostic marker for better outcome in patients with locoregional NPC, and positive protein expression and local regional lymph node metastasis can predict the progression of NPC. Pan et al (2009) reported that variants in p53 improved radiotherapeutic tumor control survival rate in patients with NPC. However, the results are inconsistent (Ho et al, 2001;Agaoglu et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma

Dong

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a cohort study to investigate whether polymorphisms in p53 at codon 72 are associated with tumor response and survival time of advanced nasopharyngeal carcinoma (NPC) patients treated with radiotherapy. The study population included 127 subjects with NPC who were enrolled at Binzhou Medical University between September 2008 and December 2009. Cox proportional hazard regression was used to assess the association between polymorphisms in the p53 gene and progression-free survival (PFS) and overall survival (OS) of NPC patients. During the follow-up period, 42 patients died and 72 patients showed progression at the end of the study. Of the 127 patients, median PFS was 22.5 ± 1.2 months (1-36 months), and the median OS time was 28.2 ± 1.1 months (2-36 months). The p53 codon 72 Pro/Pro genotype was associated with a longer median PFS time of 30.3 months compared with 18.2 months for patients with Arg/Arg variants. Moreover, the p53 codon 72 Pro/ Pro genotype was associated with a longer median OS time of 31.6 months compared with 25.8 months for those with Arg/Arg variants; the P value was marginally significant. We showed that variants in p53 codon 72 may be an independent predictor for PFS and OS of NPC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma

Dong

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…4,5 Early clinical trials have demonstrated the safety of this approach, and oncolytic viruses are now being combined with chemotherapy in various multimodal approaches of chemovirotherapy. 6 Particularly, for the treatment of advanced and/or metastasized HNSCC, Phase III clinical trials are going on using different oncolytics, which include vectors based on herpes simplex virus, adenovirus and reovirus in combination with platinum and/or taxane.…”

Section: Introductionmentioning

confidence: 99%

Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus

et al. 2011

View full text Add to dashboard Cite

First-line treatment of recurrent and/or refractory head and neck squamous cell carcinoma (HNSCC) is based on platinum, 5-fluorouracil (5-FU) and the monoclonal antiEGFR antibody cetuximab. However, in most cases this chemoimmunotherapy does not cure the disease, and more than 50% of HNSCC patients are dying because of local recurrence of the tumors. In the majority of cases, HNSCC overexpress the epidermal growth factor receptor (EGFR), and its presence is associated with a poor outcome. In this study, we engineered an EGFR-targeted oncolytic measles virus (MV), armed with the bifunctional enzyme cytosine deaminase/ uracil phosphoribosyltransferase (CD/UPRT). CD/UPRT converts 5-fluorocytosine (5-FC) into the chemotherapeutic 5-FU, a mainstay of HNSCC chemotherapy. This virus efficiently replicates in and lyses primary HNSCC cells in vitro. Arming with CD/UPRT mediates efficient prodrug activation with high bystander killing of non-infected tumor cells. In mice bearing primary HNSCC xenografts, intratumoral administration of MV-antiEGFR resulted in statistically significant tumor growth delay and prolongation of survival. Importantly, combination with 5-FC is superior to virus-only treatment leading to significant tumor growth inhibition. Thus, chemovirotherapy with EGFR-targeted and CD/UPRT-armed MV is highly efficacious in preclinical settings with direct translational implications for a planned Phase I clinical trial of MV for locoregional treatment of HNSCC.

show abstract

“…Combination therapy of rAd-p53 and radiation has demonstrated good efficacy for the treatment of multiple tumors. It has also been approved as a treatment model for certain head and neck malignancies, including nasopharyngeal carcinoma (11). Previous studies have revealed that the peak time for wt-p53 expression following Gendicine treatment was 48-72 h after transfection (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells

Han

Zhao

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

show abstract

Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma

Abstract: In patients with NPC, rAd-p53 was safe and biologically active. Our results indicated that rAd-p53 improves radiotherapeutic tumor control and survival rate in patients with NPC.

Cited by 107 publications

References 16 publications

Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma

Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma

Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus

Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells

Contact Info

Product

Resources

About